Antiretroviral therapy adherence among treatment-naive HIV-infected patients. 2020

Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
Division of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois, USA.

To determine the incidence of antiretroviral therapy (ART) adherence among treatment-naive HIV-infected patients and to evaluate the impact of single-tablet regimen (STR) on ART adherence among this population. Retrospective cohort study. We used a nationally representative sample of IQVIA LRx Lifelink individual level pharmacy claims database during 2011-2016, and defined adult patients with index date (first complete ART regimen prescription fill date) after 30 June 2011 as treatment naïve. We estimated ART adherence, measured as the proportion of days covered during 1 year following the index date. We conducted multivariable analysis to identify the factors associated with optimum adherence (≥90% proportion of days covered). We also compared adherence between patients prescribed STR and multiple-tablet regimens among those prescribed integrase strand transfer inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based regimens. Overall 42.9% of the patients were optimally adherent. Adherence was significantly lower among blacks, Hispanics and patients in low-income communities. Adjusting for the covariates, patients on STR had higher incidence of optimum adherence compared with those on multiple-tablet regimens among patients on integrase strand transfer inhibitor-based regimens [49 vs. 24%, relative risk, 2.16 (95% confidence interval: 1.96-2.26)], but no significant difference was observed among those on nonnucleoside reverse transcriptase inhibitor-based regimen [45 vs. 45%, relative risk, 1.12 (95% confidence interval: 0.99-1.26)]. Low ART adherence observed among treatment-naive patients in this nationally representative study suggests the need for public health interventions to improve adherence among this population.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013607 Tablets Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed) Tablet
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
April 2005, Journal of acquired immune deficiency syndromes (1999),
Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
November 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
February 2006, Journal of acquired immune deficiency syndromes (1999),
Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
September 2013, Le infezioni in medicina,
Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
October 2015, AIDS (London, England),
Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
January 2012, AIDS research and treatment,
Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
June 2013, Journal of the International Association of Providers of AIDS Care,
Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
February 2005, International journal of STD & AIDS,
Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
May 2016, Journal of the International Association of Providers of AIDS Care,
Apurba Chakraborty, and Dima M Qato, and Saria S Awadalla, and Ronald C Hershow, and Mark S Dworkin
August 2014, Journal of managed care & specialty pharmacy,
Copied contents to your clipboard!